Intellia Therapeutics Inc Stock News

AQR Capital Management LLC increased its stake in shares of Intellia Therapeutics Inc (NASDAQ:NTLA) by 63.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the

If you're interested in Intellia Therapeutics, Inc. (NASDAQ:NTLA), then you might want to consider its beta (a measure...

Companies in race to find treatment for genetic disease that can cause lung and liver disease Continue reading...

Alnylam, Dicerna Join Forces to Take on Arrowhead, Stocks: ALNY,DRNA,ARWR,NTLA,VRTX,NVO,ALXN,LLY,RHHBY, release date:Apr 06, 2020

What should investors think of this well-known gene-editing company?

Intellia Therapeutics (NASDAQ:NTLA)‘s stock had its “buy” rating reissued by analysts at BTIG Research in a report released on Thursday, TipRanks reports. They currently have a $22.00 price obje

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Eli Lilly & Co (LLY), Ascendis Pharma (ASND) and

Intellia Therapeutics (NASDAQ:NTLA)‘s stock had its “buy” rating reiterated by stock analysts at Chardan Capital in a research note issued on Tuesday, TipRanks reports. They presently have a $57

Oppenheimer analyst Silvan Tuerkcan maintained a Buy rating on Crispr Therapeutics AG (CRSP) yesterday and set a price target of $80.00. The company's

Oppenheimer analyst Silvan Tuerkcan maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) yesterday and set a

Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Intellia Therapeutics (NTLA) today and set a price target of $57.50. The company's

Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Intellia Therapeutics (NTLA – Research Report) today and set a

Intellia Therapeutics (NTLA -2.0%) announces that the FDA has signed off on collaboration partner Novartis' (NVS -0.6%) IND for a Phase 1/2 clinical trial evaluating a CRISPR/Cas9-based engineered cel

Intellia announces acceptance of IND application for CRISPR/CAS9-based therapy NTLA NVS

Intellia Therapeutics, Inc. (NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced that the U.S. Food